Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Implementing Heart Failure Guidelines with Collaborative Care
Start date: Aug 27, 2023 End date: Aug 27, 2023
Radcliffe Medical Education present a satellite symposium entitled ‘Implementing Heart Failure Guidelines with Collaborative Care’ at the ESC Congress 2023 in Amsterdam, NL. Join us in the Riga Lecture Room, or online, on Sunday 27 August 2023, from 12:45 to 13:45 CEST. This session, chaired by Prof Carolyn Lam (National Heart Centre Singapore, SG), provides an excellent opportunity for… View more

Heart Failure
HFA 24 Late-Breaker Discussion: The TITRATE-HF Study
Author(s): Jasper J Brugts , Harriette Van Spall Added: 1 year ago
HFA 24 - Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) joined onsite by Dr Jasper Brugts (Erasmus University Medical Centre, NL) to discuss the first results from the TITRATE-HF study.TITRATE-HF is a real-world multicenter longitudinal study which aims to assess drug sequencing strategies for guideline-directed medical therapy (GDMT) initiation in patients with de novo,… View more

Heart Failure
Polypill in Heart Failure Survey
Author(s): Raja Ezman Raja Shariff , Khairul Shafiq Ibrahim , Sazzli Kasim Added: 1 year ago

Guidelines & Statements

Heart Failure
DIGIT-HF: Digitoxin Reduces Primary Outcome in Symptomatic Heart Failure with Reduced Ejection Fraction
Added: 4 months ago Source:  Radcliffe Cardiology
AUTHOR: Yazmin SadikNew findings from the DIGIT-HF trial indicate that adding low-dose digitoxin to guideline-directed medical therapy (GDMT) can reduce the risk of hospitalisation and all-cause mortality in patients with symptomatic heart failure with reduced ejection fraction (HFrEF).¹The results were presented at the European Society of Cardiology (ESC) Congress 2025 and simultaneously… View more

Guidelines & Statements

Heart Failure
Teresa Taft Levitch is a strategic healthcare communicator, writer, and patient advocate whose work focuses on cancer rehabilitation, survivorship, and cardiovascular health. She has developed patient-centered content and campaigns for organisations including the CDC Foundation, AstraZeneca, Memorial Sloan Kettering Cancer Center, the American Heart Association, and the Cancer Survivorship &… View more
Implementation of Guidelines in Heart Failure: Why it Needs Improving
Author(s): Michel Komajda Added: 1 year ago

Guidelines & Statements

Heart Failure
AHA 25: The POLY-HF Trial
Author(s): Ambarish Pandey Added: 2 months ago
AHA Scientific Sessions 2025 – Dr Ambarish Pandey (University of Texas Southwestern Medical Center, US) presents results from the POLY-HF trial (NCT04633005), evaluating a polypill strategy combining multiple evidence-based medications for heart failure with reduced ejection fraction.This single-center randomized trial enrolled 212 patients with HFrEF (ejection fraction ≤40%) who were not… View more

Heart Failure
HFSA 25: The INTEGRA-D Trial
Author(s): Nir Uriel Added: 3 months ago
HFSA 25 - CCM-D was associated with successful defibrillation and symptom improvement in patients with HFrEF at 6 months in the INTEGRA-D Trial.Dr Nir Uriel (NewYork-Presbyterian, Columbia University Irving Medical Center, US) joins us to discuss findings from the Integra-D trial, evaluating a novel implantable device that provides both cardiac contractility modulation and defibrillation… View more

Heart Failure
ESC HF 25: The VELOCITY Study
Author(s): Stephen J Greene Added: 8 months ago
ESC HF 25 - VELOCITY shows bypassing an initiation dose of 2.5mg, and and beginning with 5mg vericiguat safe and tolerable in 9/10 patients with heart failure with ejection fraction <45%.Prof Stephen Greene (Duke Clinical Research Institute, US) discusses the findings from VELOCITY (NCT06195930; Bayer), a phase 2b open-label clinical study evaluating the tolerability and safety of an… View more

Heart Failure
HFA 24 Late-Breaker Wrap Up with Dr Van Spall & Dr Petrie
Author(s): Harriette Van Spall , Mark Petrie Added: 1 year ago
HFA 2024 — Join experts, Dr Harriette Van Spall (McMaster University, CA) and Dr Mark Petrie (University of Glasgow, UK) for an insightful wrap up of the novel data presented at 2024's Heart Failure Congress.00:24 - STEP HFpEF Programme: Semaglutide 2.4 mg and NTproBNP in obesity-related HFpEF & Semaglutide therapy and diuretic use in obesity-related HFpEF02:20 - EMPACT-MI: The effect of… View more

Demographic

Heart Failure